SI2861214T1 - Po meri narejeni liposomi za zdravljenje bakterijskih infekcij - Google Patents

Po meri narejeni liposomi za zdravljenje bakterijskih infekcij

Info

Publication number
SI2861214T1
SI2861214T1 SI201331806T SI201331806T SI2861214T1 SI 2861214 T1 SI2861214 T1 SI 2861214T1 SI 201331806 T SI201331806 T SI 201331806T SI 201331806 T SI201331806 T SI 201331806T SI 2861214 T1 SI2861214 T1 SI 2861214T1
Authority
SI
Slovenia
Prior art keywords
treatment
bacterial infections
custom made
made liposomes
liposomes
Prior art date
Application number
SI201331806T
Other languages
English (en)
Slovenian (sl)
Inventor
Eduard Babiychuk
Annette Draeger
Original Assignee
Universitaet Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Bern filed Critical Universitaet Bern
Publication of SI2861214T1 publication Critical patent/SI2861214T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
SI201331806T 2012-06-14 2013-06-13 Po meri narejeni liposomi za zdravljenje bakterijskih infekcij SI2861214T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12171924 2012-06-14
EP13153039 2013-01-29
EP13732388.7A EP2861214B1 (en) 2012-06-14 2013-06-13 Tailored liposomes for the treatment of bacterial infections
PCT/EP2013/062207 WO2013186286A1 (en) 2012-06-14 2013-06-13 Tailored liposomes for the treatment of bacterial infections

Publications (1)

Publication Number Publication Date
SI2861214T1 true SI2861214T1 (sl) 2021-01-29

Family

ID=48703423

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201331806T SI2861214T1 (sl) 2012-06-14 2013-06-13 Po meri narejeni liposomi za zdravljenje bakterijskih infekcij

Country Status (19)

Country Link
US (4) US10744089B2 (enExample)
EP (2) EP2861214B1 (enExample)
JP (2) JP6382801B2 (enExample)
CN (2) CN104602672B (enExample)
AU (2) AU2013276565B2 (enExample)
BR (1) BR112014031278B1 (enExample)
CA (1) CA2875470C (enExample)
CY (1) CY1123337T1 (enExample)
DK (1) DK2861214T3 (enExample)
ES (1) ES2821502T3 (enExample)
HR (1) HRP20201761T1 (enExample)
HU (1) HUE051761T2 (enExample)
LT (1) LT2861214T (enExample)
PL (1) PL2861214T3 (enExample)
RS (1) RS60951B1 (enExample)
RU (1) RU2672106C2 (enExample)
SI (1) SI2861214T1 (enExample)
SM (1) SMT202000584T1 (enExample)
WO (1) WO2013186286A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2861214B1 (en) 2012-06-14 2020-08-05 Universität Bern Tailored liposomes for the treatment of bacterial infections
WO2015084677A1 (en) 2013-12-02 2015-06-11 Arytha Biosciences, Llc Toxoid preparation and uses thereof
US10739353B2 (en) * 2014-12-31 2020-08-11 Signpath Pharma, Inc. Suppression of cytokine release and cytokine storm
CA3009119A1 (en) 2015-12-28 2017-07-06 Mb Biotech Ltd. Liposomes for treatment of an autoimmune disease
WO2017177073A1 (en) * 2016-04-07 2017-10-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Francisella lipids as broad anti-inflammatory therapeutics and associated methods of use
DK3471732T3 (da) 2016-06-16 2020-08-17 Combioxin Sa Liposomer til behandling af virusinfektioner
ES3060425T3 (en) 2017-03-02 2026-03-26 Combioxin Sa Liposomes for inhibiting biofilm formation
US11344497B1 (en) * 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
KR102915698B1 (ko) * 2018-04-17 2026-01-28 콤비옥신 에스에이 폐렴의 치료
PT3781210T (pt) * 2018-04-20 2024-10-02 Combioxin Sa Tratamento da hipotensão com sépsis ou choque séptico
CN111214439B (zh) * 2018-11-23 2023-02-10 复旦大学 一种具有细菌成孔毒素吸附性能的纳米药物系统及其用途
EP4093458A4 (en) 2020-01-20 2024-01-17 Arytha Biosciences LLC Devices containing cellular membrane and uses thereof
JP2023536833A (ja) * 2020-07-31 2023-08-30 サインパス ファルマ,インク. サイトカイン放出及びサイトカインストームの抑制
CN115054577B (zh) * 2022-05-17 2024-06-21 温州医科大学附属第二医院(温州医科大学附属育英儿童医院) 纳米解毒剂及其在中和mrsa穿孔毒素的应用
WO2026099472A1 (en) 2024-11-08 2026-05-15 Universität Bern Liposomal compositions for treatment of inflammation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641247A (en) 1970-12-14 1972-02-08 Stanley Drug Products Inc Methods of treating bacterial infections
WO1991004019A1 (en) * 1989-09-12 1991-04-04 The Regents Of The University Of California Therapeutic peptides and proteins
NL9000207A (enExample) * 1990-01-29 1991-08-16 Duphar Int Res
WO1993004672A1 (en) * 1991-09-11 1993-03-18 Pitman-Moore, Inc. Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US8110217B2 (en) * 2001-08-13 2012-02-07 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
US20050118250A1 (en) * 2001-11-13 2005-06-02 Paul Tardi Lipid carrier compositions with enhanced blood stability
CA2368656A1 (en) * 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
JP4187249B2 (ja) 2002-03-08 2008-11-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 プレシナプス蛋白p120
AU2003265241A1 (en) * 2002-05-23 2003-12-12 Activbiotics, Inc. Methods of treating bacterial infections and diseases associated therewith
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
WO2004087097A2 (en) * 2003-03-31 2004-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
KR101462825B1 (ko) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
AU2005304914B2 (en) * 2004-11-05 2012-02-16 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
US20090186073A1 (en) 2005-08-11 2009-07-23 National Institute Of Advanced Industrial Science And Technology Design of Delivery Vehicle Based On Rolling Model
CN1939340A (zh) * 2005-09-29 2007-04-04 中国人民解放军军事医学科学院毒物药物研究所 脂质体制剂
US20080131497A1 (en) 2006-09-28 2008-06-05 Perkins Walter R Formulations of DNase and Methods of Use Thereof
US9637515B2 (en) * 2006-11-06 2017-05-02 Jina Pharmaceuticals, Inc. Guggulphospholipid methods and compositions
CN1994279A (zh) * 2006-12-31 2007-07-11 西安力邦医药科技有限责任公司 注射用盐酸伊立替康脂质体的制备方法
US8906855B2 (en) 2007-12-22 2014-12-09 Vivacelle Bio, Inc. Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
CN101623262B (zh) * 2009-08-24 2011-02-02 海南美大制药有限公司 一种五水头孢唑啉钠前体脂质体制剂
WO2011160110A1 (en) * 2010-06-19 2011-12-22 Western University Of Health Sciences Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics
WO2012021107A2 (en) * 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
CN102327220B (zh) * 2011-07-14 2012-09-26 海南灵康制药有限公司 一种氯雷他定脂质体固体制剂
EP2861214B1 (en) 2012-06-14 2020-08-05 Universität Bern Tailored liposomes for the treatment of bacterial infections
US10716756B2 (en) 2016-06-20 2020-07-21 Vivacelle Bio, Inc. Compositions and methods for reducing reperfusion injury
ES3060425T3 (en) 2017-03-02 2026-03-26 Combioxin Sa Liposomes for inhibiting biofilm formation
KR102915698B1 (ko) 2018-04-17 2026-01-28 콤비옥신 에스에이 폐렴의 치료

Also Published As

Publication number Publication date
US10744089B2 (en) 2020-08-18
RS60951B1 (sr) 2020-11-30
US20230031648A1 (en) 2023-02-02
JP6656321B2 (ja) 2020-03-04
BR112014031278B1 (pt) 2020-12-01
AU2013276565A1 (en) 2014-12-18
LT2861214T (lt) 2020-12-28
PL2861214T3 (pl) 2021-02-08
DK2861214T3 (da) 2020-10-12
EP3782606A1 (en) 2021-02-24
RU2018138012A (ru) 2019-03-21
CN104602672A (zh) 2015-05-06
JP6382801B2 (ja) 2018-08-29
AU2013276565B2 (en) 2018-12-20
CA2875470A1 (en) 2013-12-19
US20150157570A1 (en) 2015-06-11
US20220087934A1 (en) 2022-03-24
AU2019201776B2 (en) 2020-11-12
CA2875470C (en) 2021-01-12
US20200345639A1 (en) 2020-11-05
CN104602672B (zh) 2018-12-25
RU2014148284A (ru) 2016-08-10
HK1210018A1 (en) 2016-04-15
HRP20201761T1 (hr) 2020-12-25
ES2821502T3 (es) 2021-04-26
EP2861214B1 (en) 2020-08-05
EP2861214A1 (en) 2015-04-22
CN109549925B (zh) 2022-06-17
HUE051761T2 (hu) 2021-03-29
CN109549925A (zh) 2019-04-02
JP2018184470A (ja) 2018-11-22
JP2015519383A (ja) 2015-07-09
BR112014031278A2 (pt) 2017-06-27
SMT202000584T1 (it) 2020-11-10
RU2672106C2 (ru) 2018-11-12
CY1123337T1 (el) 2021-12-31
AU2019201776A1 (en) 2019-04-04
WO2013186286A1 (en) 2013-12-19
US12599558B2 (en) 2026-04-14

Similar Documents

Publication Publication Date Title
PL2852391T3 (pl) Układy do leczenia infekcji płuc
HUE059033T2 (hu) Benzoxaborol-származékok bakteriális fertõzések kezelésére
DK2861214T3 (da) Tilpassede liposomer til behandling af bakterieinfektioner
IL240765A0 (en) Macrocyclic daza-furanones for the treatment of viral infections
ZA201405820B (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
EP2991638A4 (en) METHOD FOR TREATING BACTERIAL INFECTIONS
ZA201500921B (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diaseases
ZA201501018B (en) Compounds for the treatment of paramoxyvirus viral infections
HRP20180237T1 (hr) Metode za liječenje hcv-a
SG11201504813XA (en) Mannose derivatives for treating bacterial infections
PL2696890T3 (pl) Leczenie infekcji drobnoustrojowych
GB201217097D0 (en) Treatment of bacterial infection
EP2912186A4 (en) TARGETED THROMBOZYTE TREATMENT
EP2739764A4 (en) ION SOURCE
SE536208E (sv) Luftbehandlingssystem och sätt att styra avfrostningen av detta
DK3068232T4 (da) Mælkesyrebakteriekultur
ZA201306342B (en) The treatment of viral infections
HRP20150141T1 (xx) Upotreba nifuratela u lijeäśenju infekcija uzrokovanih klostridijima
CO6811849A2 (es) Tratamiento de infecciones bacterianas
PT2861214T (pt) Lipossomas adaptados para o tratamento de infeções bacterianas
GB201301722D0 (en) Quantifcation of bacteria
AU2013902317A0 (en) Inhibition of periodontopathogenic bacteria
AU2013901517A0 (en) Methods of Treating Bacterial Infections
EP2793897A4 (en) TREATMENT OF SEBORRHOE
FI20126161L (fi) Seinän pintakäsittely